Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2021
FDA approves Vyvgart for myasthenia gravis
The FDA approved Vyvgart for adults with myasthenia gravis who are positive for acetylcholine receptor antibody.
2021
Janssen affiliate announces end of cusatuzumab collaboration with argenx
Cilag GmbH International, a Janssen Pharmaceutical Companies of Johnson & Johnson affiliate, announced that it would not continue its collaboration and license agreement with argenx for cusatuzumab. Janssen said it would work with argenx to transition the program back to argenx.
2021
Pure MHC and argenx announce initial collaboration project
Pure MHC announced an initial collaboration project with argenx to support a more robust understanding of how antigen presentation changes in the presence of specific therapeutic agents.